O'donovan n, byrne at, o'connor ae, mcgee s, gallagher wm, crown j

2012 Publications

Brennan DJ, O'Connor DP, Laursen H, McGee SF, McCarthy S, Zagozdzon R, Rexhepaj E, Culhane
AC, Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC,
Crown JP, Jirström K, Gallagher WM. The cocaine- and amphetamine-regulated transcript mediates
ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast
cancer. Oncogene. 2012 Jul 26;31(30):3483-94. doi: 10.1038/onc.2011.519. Epub 2011 Dec 5.
PubMe
Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J. Trastuzumab induces
antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell
lines. Ann Oncol. 2012 Jul;23(7):1788-95. Epub 2011 Nov 5. PubMe
Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ,
Kennedy MJ, Lynch V, Clynes M. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA,
reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer.
2012 Aug 15;131(4):911-23. doi: 10.1002/ijc.26462. E
Geiger T, Madden SF, Gallagher WM, Cox J, Mann M. Proteomic portrait of human breast cancer
progression identifies novel prognostic markers. Cancer Res. 2012 May 1;72(9):2428-39. Epub 2012
Mar 13. PubMe
Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J,
O'Driscoll L. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target
involved in breast cancer tumorigenesis. Int J Cancer. 2012 May 1;130(9):1991-2002. doi:
10.1002/ijc.26200. Epub 2011 Aug 8. PubMe
Keenan J, Joyce H, Aherne S, O'Dea S, Doolan P, Lynch V, Clynes M. Olfactomedin III expression
contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line. Exp
Cell Res. 2012 Mar 10;318(5):593-602. Epub 2012 Jan 13. PubMe
O'Connell K, Prencipe M, O'Neill A, Corcoran C, Rani S, Henry M, Dowling P, Meleady P, O'Driscoll
L, Watson W, O'Connor R. The use of LC-MS to identify differentially expressed proteins in
docetaxel-resistant prostate cancer cell lines. Proteomics. 2012 Jul;12(13):2115-26. doi:
10.1002/pmic.201100489. PubMed
O'Neill F, Madden SF, Aherne ST, Clynes M, Crown J, Doolan P, O'Connor R. Gene expression
changes as markers of early lapatinib response in a panel of breast cancer cell lines. Mol Cancer. 2012
Jun 18;11(1):41. [Epub ahead of print] PubMed
Radziwon-Balicka A, Medina C, O'Driscoll L, Treumann A, Bazou D, Inkielewicz-Stepniak I,
Radomski A, Jow H, Radomski MW. Platelets increase survival of adenocarcinoma cells challenged
with anticancer drugs: mechanisms and implications for chemoresistance. Br J Pharmacol. 2012 Apr
17. doi: 10.1111/j.1476-5381.2012.01991.x. [Epub ahead of print] PubMe
Zagozdzon AM, O'Leary P, Callanan JJ, Crown J, Gallagher WM, Zagozdzon R. Generation of a new
bioluminescent model for visualisation of mammary tumour development in transgenic mice. BMC
Cancer. 2012 May 30;12:209. PubMed PMID: 22646761; PubMed Centra
2011 Publications

Brennan DJ, Laursen H, O'Connor DP, Borgquist S, Uhlen M, Gallagher WM, Pontén F, Millikan RC,
Rydén L, Jirström K. Tumor-specific HMG-CoA reductase expression in primary premenopausal
breast cancer predicts response to tamoxifen. Breast Cancer Res. 2011 Jan 31;13(1):R12. PubMed
PMID: 21281480; PubMed Centra
Brougham DF, Ivanova G, Gottschalk M, Collins DM, Eustace AJ, O'Connor R, Havel J. Artificial
neural networks for classification in metabolomic studies of whole cells using 1H nuclear magnetic
resonance. J Biomed Biotechnol. 2011;2011:158094. Epub 2010 Sep 15. PubMed PMID: 20886062;
PubMed Centra
Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N. Inhibition of
IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol.
2011 Jan;22(1):68-73. Epub 2010 Jul 20. PubMed
Corcoran C, Friel AM, Duffy MJ, Crown J, O’Driscoll L. Invited review: Intracellular and
extracellular microRNAs in breast cancer. Clin Chem. 2011. In press.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani
N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. Leukocyte
complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
Cancer Discov. 2011 Jun;1(1):54-67. Epub 2011 Jun 1. PubMed PMID: 22039576; PubMed Central

Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: Where are we?
Int J Cancer. 2012 May 14. doi: 10.1002/ijc.27632. [Epub ahead of print] PubMe
Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM. The ADAMs
family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics. 2011 Jun
9;8(1):9. PubMed PMID: 21906355; PubMed Centra
Duffy MJ, O'Donovan N, Crown J. Use of molecular markers for predicting therapy response in
cancer patients. Cancer Treat Rev. 2011 Apr;37(2):151-9. Epub 2010 Aug 3. Review. PubMed

Dunne G, Breen L, Collins DM, Roche S, Clynes M, O'Connor R. Modulation of P-gp expression by
lapatinib. Invest New Drugs. 2011 Dec;29(6):1284-93. Epub 2010 Jul 6. PubMe
Fox D, O'Connor R, Mallon P, McMahon G. Simultaneous determination of efavirenz, rifampicin and
its metabolite desacetyl rifampicin levels in human plasma. J Pharm Biomed Anal. 2011 Dec
5;56(4):785-91. Epub 2011 Jul 30. PubMed
Friel AM, Crown J, O'Driscoll L. Analysis of gene expression as relevant to cancer cells and
circulating tumour cells. Methods Mol Biol. 2011;784:55-75. doi: 10.1007/978-1-61779-289-2_5.
PubMe
Gately K, Kerr K, O'Byrne K. Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis. Methods Mol Biol. 2011;784:139-53. doi: 10.1007/978-1-61779-289-2_10. PubMe Germano S, O'Driscoll L. Western blotting analysis as a tool to study receptor tyrosine kinases. Methods Mol Biol. 2011;784:109-21. doi: 10.1007/978-1-61779-289-2_8. PubMe McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol. 2011 Jun;32(3):441-50. Epub 2010 Dec 14. Pub O'Connor AE, Mc Gee MM, Likar Y, Ponomarev V, Callanan JJ, O'shea DF, Byrne AT, Gallagher WM. Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo. Int J Cancer. 2012 Feb 1;130(3):705-15. doi: 10.1002/ijc.26073. Epub 2011 May 26. PubMe O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011 Oct 7;10:126. PubMed PMID: 21982118; PubMed Central Rani S, O'Brien K, Kelleher FC, Corcoran C, Germano S, Radomski MW, Crown J, O'Driscoll L. Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling. Methods Mol Biol. 2011;784:181-95. doi: 10.1007/978-1-61779-289-2_13. PubMe Sheridan H, Nestor C, O'Driscoll L, Hook I. Isolation, structure elucidation, and cytotoxic evaluation of furanonaphthoquinones from in vitro plantlets and cultures of Streptocarpus dunnii. J Nat Prod. 2011 Jan 28;74(1):82-5. Epub 2010 Dec 21. Pub Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. PubMed PMID: 21991949; PubMed Centra Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 2011 Oct;22(10):2234-40. Epub 2011 Feb 28. PubMe van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discov Today. 2011 Mar;16(5-6):219-28. Epub 2011 Jan 22. Review. PubMed Zagozdzon R, Gallagher WM, Crown J. Truncated HER2: implications for HER2-targeted therapeutics. Drug Discov Today. 2011 Sep;16(17-18):810-6. Epub 2011 Jun 16. Review. PubMed 2010 Publications

Brennan DJ, O’Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Antibody-based proteomics: fast-
tracking molecular diagnostics in oncology. Nat Rev Cancer 2010; 10(9):605-17.
Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O’Donovan N. Inhibition of
IGF1R activity enhances response to trastuzumab in HER-2 positive breast cancer cells. Ann Oncol.
2010; In press.
Collins DM, Crown J, O’Donovan N, Devery A, O’Sullivan F, O’Driscoll L, Clynes M, O’Connor R.
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent
of growth factor receptor status in lung cancer cell lines. Invest new Drugs. 2010 28(4):433-44.
Corcoran C, Friel AM, Duffy MJ, Crown J, O’Driscoll L. Invited review: Intracellular and
extracellular microRNAs in breast cancer. Clin Chem. 2011. In press.
Duffy MJ, O’Donovan N, Crown J. Use of molecular markers for predicting therapy response in
cancer patients. Cancer Treat Rev. 2010; In press.
Dunne G, Breen L, Collins DM, Roche S, Clynes M, O’Connor R. Modulation of P-gp expression by
lapatinib. Invest New Drugs. 2010; In pre
Friel AM, Corcoran C, Crown J, O’Driscoll L. Relevance of circulating tumour cells, extracellular
nucleic acids and exosomes in breast cancer. Breast Cancer Res Treat. 2010 123(3):613-25.
Friel AM, Crown J, O’Driscoll L. Analysis of gene expression as relevant to cancer cells and
circulating tumour cells. Meth. Mol. Biol. 2010; Book chapter. In press.
Germano S, Rani S, Kennedy S, Crown J, Clynes M, O’Driscoll L. Melanoma-associated antigen
family protein-D4 (MAGED-4): clinical significance and functional relevance in breast cancer. Breast
Cancer Res. Treat 2010:210(12):S10-11. PubMe
Madden SF, Carpenter SB, Jeffery IB, Bjorkbacka H, Fitzgerald KA, O’Neill LA, Higgins DG.
Detecting microRNA activity from gene expression data. BMC Bioinformatics. 2010 18(11):257.

O’Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT. Review Article. Bioluminescent
imaging: a critical tool in pre-clinical oncology research. J Pathol. 2010; 220 (3): 317-327.
O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan
N, Slamon DJ. Activated Phosphoinositide 3-Kinase/AKT signaling confers resistance to trastuzumab
but not lapatinib. Mol Can Ther 2010; 9(6):1489-5
O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction
between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer
cells. Invest New Drugs. 2010; In Pre
Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher
WM. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in
breast cancer. BMC Cancer. 2010 Nov 23;10:639. PubMed PMID: 21092276; PubMed Central

Sheikh R, Walsh N, Clynes M, O'Connor R, McDermott R. Challenges of drug resistance in the
management of pancreatic cancer. Expert Rev Anticancer Ther. 2010 Oct;10(10):1647-61. Review.
PubMe
Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D,
Pierce A, O'Donovan N, Crown J, Duffy MJ. Src: a potential for the treatment of triple-negative
breast cancer. Ann Oncol. 2011 Oct;22(10):2234-40. Epub 2011 Feb 28. PubMe
van der Meel R, Gallagher WM, Oliveira S, O’Connor AE, Schiffelers RM, Byrne AT. Recent
advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies.
Drug Discov Today. 2010; 15 (3&4): 102-114
Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I,
Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O’Driscoll L. Membrane transport proteins in human
melanoma: associations with tumour aggressiveness and metastasis. Br J Cancer. 2010;102(7):1157-
62
2009 Publications

Byrne AT, O'Connor AE, Hall M, Murtagh J, O'Neill K, Curran KM, Mongrain K, Rousseau JA,
Lecomte R, McGee S, Callanan JJ, O'Shea DF, Gallagher WM. Vascular-targeted photodynamic
therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging
approach to therapeutic assessment. Br J Cancer. 2009; 101(9):1565- 1573.
Corkery B, Crown J, Roche S, O’Connor R, Tryfanopoulos D, Clynes M, O’Donovan N. Constitutive
activation of Src kinase as a mechanism of resistance to dasatinib in triple negative breast cancer.
Cancer Res. 2009; 69(24):787s
Roche S, McMahon G, Clynes M, O'Connor R. Development of a high-performance liquid
chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine
kinase inhibitors lapatinib and dasatinib. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;
877(31): 3982-90.

Source: http://www.mtci.ie/images/uploads/file/2009-12%20MTCI%20publications%20(PDF).pdf